Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162084 · ClinicalTrials.gov registry record · Phase 3
A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography
A Phase 3 study, sponsored by Forest Laboratories.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,000
- Enrollment target
NCT00162084 is a Phase 3 study that was terminated before completion, run by Forest Laboratories. The registered enrollment target is 2,000 participants.
The verdict
NCT00162084, a Phase 3 study, was terminated before completion, sponsored by Forest Laboratories.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether BMS068645 is as effective as Adenosine SPECT at detecting blockages in heart arteries, and to determine if it will have fewer side effects
Interventions
- DRUG apadenoson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2005-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162084
The ClinicalTrials.gov registry entry for NCT00162084 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apadenoson is the first listed.
NCT00162084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00162084 about?
NCT00162084 is a clinical study titled "A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography". The purpose of the study is to determine whether BMS068645 is as effective as Adenosine SPECT at detecting blockages in heart arteries, and to determine if it will have fewer side effects
What is the current status of trial NCT00162084?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,000 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00162084?
The interventions under investigation include: apadenoson (DRUG).
Who is sponsoring clinical trial NCT00162084?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.